Next |
home / stock / tenx / tenx message board
Subject | By | Source | When |
---|---|---|---|
Im new to this stock are they or | hawkshaw812 | investorshub | 04/05/2023 7:54:35 AM |
Where you seeing the news do you have | hawkshaw812 | investorshub | 04/03/2023 7:35:36 PM |
News is out, take a look. | I-CLICKED-IT-2 | investorshub | 04/01/2023 8:27:35 PM |
Bound to happen | hawkshaw812 | investorshub | 03/30/2023 8:38:27 PM |
Maybe when they release financials or reveal | timetomakemoney | investorshub | 03/30/2023 4:40:42 PM |
Is thing ever going to move | hawkshaw812 | investorshub | 03/30/2023 5:36:49 AM |
Grabbed a 1000 shares at .545 and at .535 | timetomakemoney | investorshub | 03/23/2023 2:15:16 PM |
I don't know. | timetomakemoney | investorshub | 03/23/2023 1:48:52 PM |
so whats the time frame for approval 12 | peterus | investorshub | 03/23/2023 1:45:12 PM |
So will I. IMO, a Buy | timetomakemoney | investorshub | 03/23/2023 1:43:48 PM |
will buy more on the dips | peterus | investorshub | 03/23/2023 1:20:39 PM |
Not bad my average is .605 | timetomakemoney | investorshub | 03/23/2023 1:19:26 PM |
bought 0.58 litlle gambler | peterus | investorshub | 03/22/2023 5:30:28 PM |
whats soon bro weeks ... months ? | peterus | investorshub | 03/22/2023 4:49:02 PM |
SOOOOON, My hunch those who are interested to | timetomakemoney | investorshub | 03/22/2023 4:42:12 PM |
whats up with fda ? | peterus | investorshub | 03/22/2023 4:35:23 PM |
The Patent has been granted, now come bids | timetomakemoney | investorshub | 03/22/2023 4:00:21 PM |
Volume is descent. The patent is great news. | timetomakemoney | investorshub | 03/22/2023 2:53:07 PM |
lol red zero intrest from traders just new bagholders | peterus | investorshub | 03/22/2023 1:49:10 PM |
Co has the patent and need a buyout | shurtha2000 | investorshub | 03/22/2023 1:37:35 PM |
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF ...